

**Remarks**

Reconsideration of the above patent application is respectfully requested.

Applicants affirm the election to prosecute the invention of Group I, claims 1-28, made by the undersigned attorney on March 28, 2002.

The Examiner rejects claims 1-10 and 17-28, under 35 U.S.C. § 102, as being anticipated by Bakshi et al, WO 01/91752, which has a priority date of May 30, 2000 based upon U.S. Provisional Application 60/207,918.


Applicants respectfully submit that claim 1, as amended, and the cancellation of claims 2-10 and 17-28 have rendered the Examiner's rejection moot.

Applicants acknowledge that claim 1 (previously claim 11) and claims 12-16 are in condition for allowance as rewritten in independent form.

Reconsideration of claims 1 and 12-16 and early allowance thereof is respectfully requested.

Respectfully submitted,

Date: May 28, 2004

  
B. Timothy Creagan  
Attorney for Applicant(s)  
Reg. No. 39,156

Pfizer Inc  
Patent Department  
Eastern Point Road, MS8260-1611  
Groton, Connecticut 06340  
(860) 715-4546